Janssen Initiates Clinical Study for Psoriasis

To help address health inequities in treating psoriasis, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the initiation of VISIBLE, a large-scale prospective clinical study dedicated to people of color living with moderate to severe plaque and/or scalp psoriasis.

VISIBLE will further evaluate the efficacy and safety of TREMFYA® (guselkumab) in people of color to generate additional data and provide valuable information about disease burden and the psoriatic disease patient journey in this population.

Read more about Janssen's new clinical study here.